Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-05-03
Target enrollment:
Participant gender:
Summary
This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating
patients with solid tumors that have come back (relapsed) or does not respond to treatment
(refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.